Preparation of gelatin/Ag NPs under ultrasound condition: A potent and green bio-nanocomposite for the treatment of pleomorphic hepatocellular carcinoma, morris hepatoma, and novikoff hepatoma

Regarding applicative, facile, green chemical research, a bio-inspired approach is being reported for the sonochemical synthesis of Ag nanoparticles by gelatin as a natural reducing/stabilizing and solid support agent without using any toxic and harmful reagent. The biosynthesized Ag NPs@gelatin bionanocomposite were characterized by advanced physicochemical techniques like ultraviolet–visible (UV–Vis), Fourier Transformed Infrared spectroscopy (FT-IR), Scanning Electron Microscopy (SEM), High-Resolution Transmission Electron Microscopy (HR-TEM), Energy Dispersive X-ray spectroscopy (EDX), and X-ray Diffraction (XRD) study. It has been established that gelatin-stabilized silver nanoparticles have a spherical shape with a mean diameter from ∼5–10 nm. To survey the antioxidant potentials of Ag NPs@gelatin, one of the common antioxidant techniques i.e., DPPH was used. The results of DPPH test proved excellent antioxidant properties of Ag NPs@gelatin in comparison to the positive control used i.e., butylated hydroxytoluene. The IC50 of Ag NPs@gelatin was 250 µg/mL in the antioxidant test. Determination of anti-liver cancer effects of Ag NPs@gelatin was carried out by the MTT assay and against pleomorphic hepatocellular carcinoma (SNU-387), morris hepatoma (McA-RH7777), and novikoff hepatoma (N1-S1 Fudr) cell lines. The results of MTT assay confirmed removing SNU-387, McA-RH7777, and N1-S1 Fudr cell lines after treating with low concentrations of Ag NPs@gelatin. The IC50 of the Ag NPs@gelatin was 192, 144, and 228 µg/mL against SNU-387, McA-RH7777, and N1-S1 Fudr cell lines, respectively. The best result of anti-human liver cancer effects of Ag NPs@gelatin against the above cell lines was seen in the case of the N1-S1 Fudr cell line. According to the above results, significant anti-liver cancer effects of Ag NPs@gelatin is confirmed.